DelveInsight’s “Mesothelioma Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Mesothelioma pipeline landscapes.
The report comprises Mesothelioma pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Mesothelioma therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Mesothelioma pipeline products.
Mesothelioma Overview
Mesothelioma is a rare, aggressive form of malignant tumor that is caused by inhaled asbestos fibers and forms in the lining of the lungs, abdomen, or heart. There are four primary types of mesothelioma based on tumor location: Pleural Mesothelioma (MPM), Peritoneal Mesothelioma, Pericardial Mesothelioma, and Testicular Mesothelioma. Pleural mesothelioma is a cancer of the pleura, which is the mesothelium surrounding the lungs and it is the most common type of mesothelioma, accounting for 80 – 90% of all diagnosed cases. Because males are exposed to asbestos more often, they are more likely to be diagnosed with mesothelioma.
Some of the key takeaways from the Mesothelioma Pipeline Report:
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Trizell Ltd, AstraZeneca, Momotaro-Gene, TCR2 Therapeutics, Roche, etc., are developing therapies for the treatment of Mesothelioma.
Emerging therapies such as TR002, TC-210 T-Cells, MTG201, Imfinzi, Tecentriq Plus Avastin, are expected to have a significant impact on the Mesothelioma market in the coming years.
Get an overview of pipeline landscape @ Mesothelioma Clinical Trials Analysis
Mesothelioma Pipeline Therapies along with Key Players:
TR002: Trizell
TC-210 T-Cells: TCR2 Therapeutics
MTG201: Momotaro-Gene
Imfinzi: AstraZeneca
Tecentriq Plus Avastin: Roche
Scope of Mesothelioma Pipeline Drug Insight
Coverage: Global
Major Players: Trizell Ltd, AstraZeneca, Momotaro-Gene, TCR2 Therapeutics, Roche, and others.
Pipeline Therapies: TR002, TC-210 T-Cells, MTG201, Imfinzi, Tecentriq Plus Avastin, and others.
Table of Contents
1
Mesothelioma Report Introduction
2
Mesothelioma Executive Summary
3
4
Mesothelioma- Analytical Perspective In-depth Commercial Assessment
5
Mesothelioma Pipeline Therapeutics
6
Mesothelioma Late Stage Products (Phase II/III)
7
Mesothelioma Mid Stage Products (Phase II)
8
Mesothelioma Early Stage Products (Phase I)
9
Mesothelioma Preclinical Stage Products
10
Mesothelioma Therapeutics Assessment
11
Mesothelioma Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Mesothelioma Key Companies
14
Mesothelioma Key Products
15
Mesothelioma Unmet Needs
16
Mesothelioma Market Drivers and Barriers
17
Mesothelioma Future Perspectives and Conclusion
18
Mesothelioma Analyst Views
19
Appendix
20
About DelveInsight
Get a customized pipeline report @ Mesothelioma Drugs Pipeline Report.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/